EFFECT OF PLASMATHERAPY ON THE IMMUNE STATUS OF PATIENTS WITH VITILIGO

Authors
F.M. Rakhmonov K.M. Mukhamadieva M.S. Valieva
Job:
Department of dermatovenereology named after Professor Zoirov P.T., Avicenna Tajik State Medical University, Dushanbe, Tajikistan
DOI:
10.65197/3106-4035-2025-1-2-76-87

Annotation

Resume.

Goal. To study the effect of plasmatherapy on immune status indicators in patients with vitiligo.

Material and methods. A total of 115 patients aged 25 to 44 years with a diagnosis of vitiligo were examined, including 43 men and 72 women. Nonsegmental vitiligo (NSV) was observed in 50 patients (43.5%), while segmental vitiligo (SV) was present in 65 patients (56.5%). The study assessed CD3, CD4, CD8, CD95 markers, the immunoregulatory index (IRI), and interleukin6 (IL6) levels before and after plasmatherapy. A control group of 20 healthy individuals matched by sex and age was used for comparison

Results. Changes in immune status were detected in 98 patients (85.2%), including 50 with NSV (51.0%) and 48 with SV (49.0%). Positive dynamics after plasmatherapy were reflected in improvements of CD3, CD4, CD8, and IRI values. Normalization of CD20 and CD95 levels was observed, especially in SV patients, who also showed a marked decrease in immunoglobulin G levels. IL6 levels in SV patients decreased 1.3 times more than in NSV patients. Plasmatherapy led to restoration of immune parameters in 72 patients (73.5%). Improvement in immune indicators was 1.

Conclusion. Plasmatherapy can be recommended as an effective and safe adjunct to comprehensive vitiligo treatment for immune correction and slowing depigmentation progression, particularly in the segmental form.

Keywords

segmental vitiligo non-segmental vitiligo immune status plasmatherapy

Full text

The article is in PDF format

List of literature

  2. 1 Jafarzadeh A., Pour Mohammad A., Khosravi M., Amiri S., Rasouli A., Keramati H., Goodarzi A. A systematic review of case series and clinical trials investigating systemic oral or injectable therapies for the treatment of vitiligo. Skin Research and Technology. 2024; 30(3): 13642. doi.org/10.1111/srt.13642
  3. 2 Everts P., Onishi K., Jayaram P., Lana J.F., Mautner K. Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020. Int J Mol Sci. 2020; 21(20): 7794. DOI: 10.3390/ijms21207794
  4. 3 Lin M.Y., Lin C.S., Hu S., Chung W.H. Progress in the Use of Platelet-rich Plasma in Aesthetic and Medical Dermatology. J Clin Aesthet Dermatol. 2020; 13(8): 28–35.
  5. 4 Kaushik A., Kumaran M.S. Platelet-Rich Plasma: The Journey so Far! Indian Dermatol Online J. 2020; 11(5): 685–692.
  6. 5 Gentile P. Autologous activated platelet-rich plasma (AA-PRP) and non-activated (A-PRP) in hair growth: a retrospective, blinded, randomized evaluation in androgenetic alopecia. Expert Opin Biol Ther. 2020; 20(3): 327–337.
  7. 6 Mercuri S.R., Vollono L., Paolino G. The usefulness of platelet-rich plasma (PRP) for the treatment of vitiligo: state of the art and review. Drug design, development and therapy. 2020; 1749-1755.
  8. 7 Mercuri S.R., Di Nicola M.R., Brianti P., Bianchi V.G., Paolino G. Pilot study on the use of the "monocyte-rich" platelet-rich plasma in combination with 1927 nm fractional and 308 nm excimer lasers for the treatment of vitiligo. Medicina. 2021; 57(9): 904.
  9. 8 Earlia N., Lestari W., Bulqiah M., Fajrina N., Maulana M.N., Tasrif A.Y. The usefulness of platelet-rich plasma (PRP) as an adjuvant therapy for the treatment of vitiligo: a systematic review. IOP Conference Series: Earth and Environmental Science. IOP Publishing. 2024; 1356(1): 012122.
  10. 9 Шаймонов А.Х. Клеточные технологии в ведении больных с послеожоговыми рубцами различной локализации. Здравоохранения Таджикистана. 2025; 1: 95-100.
  11. 10 Ходжамурадов Г.М., Давлатов А.А., Мирзоев Н.М., Шаймонов А.Х., Юнусов И.А., Шамсов Н.Х. Послеоперационная профилактика развития рубцов, посредством клеточных технологий, у лиц с последствиями ожогов. Вестник Смоленской государственной медицинской академии. 2021; 20(2): 125-129.
  12. 11 Шаймонов А.Х., Мирзоев Н.М., Шамсов Н.Х., Джононов Д.Д., Юнусов И.А., Хамидов Н.Х. Применение обогащённой тромбоцитами плазмы крови при хирургическом лечении последствий ожогов. Вестник последипломного образования в сфере здравоохранения. 2021; 1: 87-91.
  13. 12 Юнусов А.И., Шаймонов А.Х., Каримзода Б.Д., Муминджанов С.А., Курбанов С.Х., Махмаджонов Б.К., Шарипов А.А. Современное состояние и перспективы применения аутологичных клеток в хирургии и травматологии. Вестник Академии медицинских наук Таджикистана. 2020; 10(1 (33)): 78-86.
  14. 13 Морозов А.М., Дадабаев В.К., Куркова В.В., Семенова С.М., Потоцкая Л.А., Беляк М.А. Эффективность применения плазмотерапии при различных нозологиях. Врач. 2023; 34(7): 37–40. https://doi.org/10.29296/25877305-2023-07-07
Information
Language

English

License

CC BY 4.0

Category

Dermatovenereology

FINANCING

There was no financial support.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

INFORMATION ABOUT THE AUTHORS:

Рахмонов Фирдавс Махмадсалимо- вич – соискатель кафедры дерматове- нерологии имени профессора П.Т. Зои- рова ГОУ “Таджикский государственный медицинский университет им. Абуали ибни Сино”, Душанбе, Таджикистан.
Мухамадиева Кибриёхон Мансуров- на – доктор медицинских наук, профес- сор, заведующая дерматовенерологии имени профессора П.Т. Зоирова ГОУ “Тад- жикский государственный медицинский университет им. Абуали ибни Сино”, Ду- шанбе, Таджикистан.
E-mail: kibriyo_67@mail.ru
http://orcid.org/0000-0002-4264-2816
Валиева Мухаббат Сайдалиевна – кандидат медицинских наук, доцент ка- федры дерматовенерологии имени про- фессора П.Т. Зоирова ГОУ “Таджикский государственный медицинский универ- ситет им. Абуали ибни Сино”, Душанбе, Таджикистан.
E-mail: muhabbat_v71@mail.ru
https://orcid.org/0000-0001-8702-0968

*Correspondence address.